scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.CEB.2015.10.004 |
P8608 | Fatcat ID | release_wrvkk2uekzcq7fy7fgdsgm7wi4 |
P698 | PubMed publication ID | 26512454 |
P50 | author | Andrew A Guirguis | Q61090111 |
P2093 | author name string | Benjamin L Ebert | |
P921 | main subject | myelodysplastic syndrome | Q954625 |
P304 | page(s) | 61-67 | |
P577 | publication date | 2015-10-26 | |
P1433 | published in | Current Opinion in Cell Biology | Q13505682 |
P1476 | title | Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond | |
P478 | volume | 37 |
Q38649220 | Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others. |
Q33433453 | Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide |
Q58299695 | IMiD compounds affect CD34 cell fate and maturation via CRBN-induced IKZF1 degradation |
Q39166988 | Immune defects caused by mutations in the ubiquitin system |
Q48226736 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. |
Q57035464 | PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs |
Q50853038 | Specific targeting of the deubiquitinase and E3 ligase families with engineered ubiquitin variants |
Q92955229 | Targeting chromatin complexes in fusion protein-driven malignancies |
Q41619260 | Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature |
Q42101565 | pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase |
Search more.